Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Neumora Therapeutics, Inc. (NMRA : NSDQ)

• Company Description    Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. Its therapeutic pipeline currently consists of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora Therapeutics Inc. is based in WATERTOWN, Mass. Number of Employees: 110

• Price / Volume Information    Yesterday's Closing Price: $1.66 Daily Weekly Monthly 20 Day Moving Average: 361,367 shares Shares Outstanding: 161.95 (millions) Market Capitalization: $268.83 (millions) Beta: 2.91 52 Week High: $17.19 52 Week Low: $0.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.06% 3.17% 12 Week 112.82% 93.22% Year To Date -84.34% -86.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 260 ARSENAL PLACE SUITE 1 - WATERTOWN,MA 02472 USA ph: 857-760-0900 fax: - investors@neumoratx.com http://www.neumoratx.com

• General Corporate Information    Officers Paul L. Berns - Chief Executive Officer Joshua Pinto - President Michael Milligan - Chief Financial Officer Kristina M. Burow - Director Matthew K. Fust - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 640979100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 161.95 Most Recent Split Date: (:1) Beta: 2.91 Market Capitalization: $268.83 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.29 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.47 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 10.81% vs. Previous Quarter: 21.43% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -98.95 03/31/25 - -84.79 12/31/24 - -68.98 ROA 06/30/25 - -87.68 03/31/25 - -77.57 12/31/24 - -63.98 Current Ratio 06/30/25 - 10.54 03/31/25 - 8.98 12/31/24 - 10.51 Quick Ratio 06/30/25 - 10.54 03/31/25 - 8.98 12/31/24 - 10.51 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 1.13 03/31/25 - 1.41 12/31/24 - 1.78 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.11 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 9.61 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©